Zhu et al., using a HFD-induced NAFLD mouse model, showed that body weight, LFTs, lipid profile, glucose, and insulin tolerance as well as hepatic steatosis were improved after 4 weeks of liraglutide treatment. This evidence concerns the gene INS and fatty liver disease.